Page 9 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

Genomic Assay Changes Minds on HER2+ Breast Cancer Treatment

Results from a prognostic genomic assay convinced a group of Spanish oncologists to change treatment plans for 56% of 89 patients with HER2-positive (HER2+) early breast cancer. ....

Comunidad Autonoma De Cataluna , Olga Mart , Kent Hoskins , University Of Barcelona , University Of Illinois At Chicago , European Society For Medical Oncology , European Society , Medical Oncology , Breast Cancer , Hospital Clinic , Alignant Breast Neoplasm , Genetic Testing , Genomic Medicine , Edicine Genomic , Alignant Neoplasia , Antineoplastic Drug , Nti Cancer Agents , Biologic Therapy , Polymerase Chain Reaction , Humanized Monoclonal Antibod ,

New HER2 Drug for Breast Cancer Stalled by FDA

The FDA said it needs more data the new antibody-drug conjugate (ADC) trastuzumab duocarmazine for use in advanced or metastatic breast cancer. ....

United Kingdom , United States , Marco Timmers , Drug Administration , European Union , Metastatic Breast Carcinoma , Antineoplastic Drug , Nti Cancer Agents , Biologic Therapy , Humanized Monoclonal Antibody , Breast Cancer , Alignant Breast Neoplasm , Her2 Positive Breast Cancer , Her2 Breast Cancer , Alignant Neoplasia , Antibody Drug Conjugates Adcs ,

T-DXd for HER2-Low BC: Analysis Confirms Adverse Effects

A safety analysis following a randomized phase 3 trial confirms that vomiting and nausea are common in patients who take the drug trastuzumab deruxtecan to treat HER2-low metastatic breast cancer. ....

United States , San Francisco , Daiichi Sankyo , Roche Genentech , Tanja Fehm , Porto Alegre , Gustavo Werutsky , European Society For Medical Oncology Breast Cancer , University Of California , University Hospital , Hope Rugo , European Society , Medical Oncology Breast Cancer , New England Journal , Moinhos De Vento Hospital , Scorpion Therapeutics , Taiho Oncology , Metastatic Breast Carcinoma , Biologic Therapy , Breast Cancer , Alignant Breast Neoplasm , Antineoplastic Drug , Nti Cancer Agents , Alignant Neoplasia , Targeted Therapy , Humanized Monoclonal Antibody ,

Hagop Kantarjian, MD, Honored by ASCO for Leukemia Research

Kantarjian receives the highest honor from the American Society of Clinical Oncology (ASCO) for his lifelong contributions to leukemia research and patient care. ....

United States , Kenneth Mccredie , Michael Keating , Davida Karnofsky , Hagop Kantarjian , Emil Freireich , Department Of Leukemia , American University Of Beirut , American Lebanese Medical Association Lifetime Achievement Award , Society Of Hematologic Oncology , Rice Baker Institute , University Of Texas Md Anderson Cancer Center , American Society Of Clinical Oncology , Leukemia Society Of America Special , Samsung Distinguished University , Memorial Award , American Society , Clinical Oncology , Medscape Medical , Samsung Distinguished University Chair , Cancer Medicine , American University , Leukemia Outcomes , Hematologic Oncology , Leukemia Fellowship , American Lebanese Medical Association ,

CLL: Venetoclax Combos Top First-Line Chemoimmunotherapy

A combination of venetoclax, ibrutinib, and obinutuzumab outperforms first-line chemoimmunotherapy for chronic lymphocytic leukemia in otherwise fit adults with few comorbidities. ....

Barbara Eichhorst , John Byrd , Jennifer Woyach , University Of Cologne Germany , Ohio State University , University Of Cincinnati , New England Journal , Chronic Lymphocytic Leukemia , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Monoclonal Antibody , Tyrosine Kinase Inhibitor , Residual Disease , Tyrosine Kinase , Atrial Fibrillation , F Atrial Fibrillation ,